ANTIMICROBIALS STEWARDSHIP PROGRAMME FOCUSED ON LONG DURATION TREATMENTS: PRELIMINARY RESULTS
CP-038
USE AND ECONOMIC IMPACT OF INTRAVENOUS IMMUNOGLOBULIN AT A UNIVERSITY HOSPITAL
CP-037
USE OF CHITOSAN FILM FOR REFRACTORY PAIN IN PERIOSTOMAL ULCER
CP-035
EVALUATION OF THE THERAPEUTIC STRATEGIES USED FOR THE TREATMENT OF THE HEPATITIS C VIRUS GENOTYPE 3 INFECTION
CP-034
EFFECTIVINESS OF THE COMBINATION LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF THE HEPATITIS C VIRUS INFECTION
CP-032
EVALUATION OF BOOSTED PROTEASE INHIBITOR MONOTHERAPY WITH DARUNAVIR/RITONAVIR IN HIVINFECTED PATIENTS. STUDY IN A REAL LIFE SETTING.
CP-028
SAFETY AND TOLERABILITY OF COMPOUNDED TOPICAL TACROLIMUS
CP-027
EFFICACY OF COMPOUNDING TOPICAL TACROLIMUS FOR SUBEPITHELIAL CORNEAL INFILTRATES TREATMENT
CP-024
FACTORS AFFECTING UPTAKE OF BIOSIMILARS
CP-023
USE OF INTRAVITREAL ANTIANGIOGENIC DRUG IN A LARGE STUDY IN THE TREATMENT OF RETINOPATHY OF PREMATURITY
CP-020
SWITCHING TO DOLUTEGRAVIR IN MONOTHERAPY
CP-019
RISK FACTORS FOR ANAEMIA DEVELOPMENT DURING THERAPY WITH RIBAVIRIN PLUS DIRECT-ACTING ANTIVIRALS
CP-018
EFFECTIVENESS OF OMALIZUMAB ON ASTHMATIC PATIENTS
CP-017
EFFICACY AND SAFETY OF NIVOLUMAB IN A TERTIARY HOSPITAL: EARLY ACCESS PROGRAM
CP-011
INFLUENCE OF SURGICAL STRATEGY AND BASELINE CONDITIONS VERSUS CYP2C19 POLYMORPHISMS IN ANTIPLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS UNDERGOING PERCUTANEUS TRANSLUMINAL ANGIOPLASTY
